NanoGuardian's On-Dose NanoEncryption Brand Protection Technology to Be Presented at AAPS Annual Meeting

SKOKIE, IL--(Marketwire - Oct 11, 2012) - NanoGuardian™, a division of NanoInk®, Inc. that delivers on-dose brand protection solutions to the pharmaceutical industry to fight counterfeiting and illegal diversion, announced today that it will give a poster presentation at the American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exhibition, which is being held on October 14 - 18, at McCormick Place in Chicago. The abstract, "Can Nanofabrication be used to Combat Counterfeit Medicines by Applying On-dose Authentication Features without Disrupting the Integrity of the Medicine?" will be presented on Monday, October 15, from 1:30 to 4:30 p.m. in Hall F by Bjoern Rosner, director of research and development, brand protection for NanoGuardian.

"Counterfeit medicines have become such a problem that pharmaceutical manufacturers are evaluating how to best ensure the integrity of their medicines for patients early in the drug development process," said Dean Hart, chief commercial officer of NanoGuardian. "The AAPS poster presentation will demonstrate that NanoGuardian's NanoEncryption technology can be used to incorporate highly sophisticated nanoscale, authentication, and tracing features directly on film-coated tablets, gelatin capsules, and vial caps without affecting the dissolution or stability of the medication -- important considerations in the development and commercialization of a new medication."

NanoGuardian's NanoEncryption technology is the only on-dose, multi-layered, brand protection solution that enables pharmaceutical manufacturers to authenticate and trace every single dose, from plant to patient. NanoGuardian's Closed-Loop Protection Program combines the on-dose authentication and tracing benefits of NanoEncryption technology with a proactive supply chain auditing program to identify counterfeit or illegally diverted pharmaceuticals entering the global supply chain as early as possible.

NanoGuardian fights both counterfeiting and illegal diversion with a single technology that can be used to protect capsules, tablets, vial caps, and single-use syringes providing a layered security of overt, covert, and forensic features. The overt and covert security features allow dose-level authentication at any point in the supply chain, while the forensic and nano-scale NanoCodes provide comprehensive tracing information on each and every dose. NanoGuardian's technology provides a strong benefit over other on-dose technologies given that NanoGuardian's security features are implemented with no additional material or chemicals being added to the medication.

As evidence of the rapidly growing problem of counterfeit pharmaceuticals, a recent report from the U.S. Customs and Border Protection and the U.S. Immigration and Customs Enforcement noted that the domestic value of counterfeit pharmaceutical seizures in fiscal year 2011 rose by more than $11 million, an increase of almost 200 percent. The implications for victims of counterfeit drugs are extremely serious, often resulting in unexpected side effects, severe allergic reactions and even death.

AAPS provides a dynamic international forum for the exchange of knowledge among scientists to enhance their contributions to health. It offers timely scientific programs, ongoing education, opportunities for networking, and professional development. More information is available at: www.aaps.org.

About NanoGuardian
NanoGuardian™, a division of NanoInk®, Inc., focuses exclusively on delivering brand protection solutions to fight illegal diversion and counterfeiting. Anchored by NanoInk's novel NanoEncryption™ technology, NanoGuardian enables manufacturers to authenticate and trace the integrity of their products across the supply chain. More information about NanoGuardian is available at www.nanoguardian.net.

NanoInk, NanoGuardian, NanoEncryption and the NanoGuardian logo are trademarks or registered trademarks of NanoInk, Inc.